熱門資訊> 正文

AIM ImmunoTech GAAP每股收益为-0.43美元

2026-08-10 20:40

AIM ImmunoTech press release (AIM): Q2 GAAP EPS of -$0.43.
As of June 30, 2026, AIM reported $9.9 million in cash and cash equivalents, as compared to approximately $3.0 million as of December 31, 2025.

More on AIM ImmunoTech

AIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential Role in Addressing BundiBugyo Ebola Outbreak Transcript
AIM ImmunoTech announces $2.65M financing priced at-market
Seeking Alpha’s Quant Rating on AIM ImmunoTech
Historical earnings data for AIM ImmunoTech
Financial information for AIM ImmunoTech

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。